ALK and non-small cell lung carcinoma: Recent efforts to characterize molecular subclassifications of NSCLC have provided a marked benefit to patients whose tumors harbor specific genetic alterations [2–4], and the three major driver oncogenic mutations are epidermal growth factor receptor (EGFR) mutation, KRAS mutation, and anaplastic lymphoma kinase (ALK) rearrangement.